MedPath

Phase II trial of docetaxel (T), cisplatin (P) and fluorouracil (5-FU) in the treatment of metastatic penile cancer

Phase 2
Recruiting
Conditions
patients with metastatic penile cancer
Registration Number
JPRN-UMIN000002697
Lead Sponsor
Fudan University Shanghai Cancer Center
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Recruiting
Sex
Male
Target Recruitment
40
Inclusion Criteria

Not provided

Exclusion Criteria

1) Usage of experimental drugs 2) History of serious drug allergy or hypersensitivity with cisplatin or paclitaxel 3) Peripheral neuropathy 4) Ototoxicity 5) Uncontrolled infection 6) Double cancer 7) Coexisting severe medical conditions 8) Mental disease 9) Judged as inappropriate to participate this trial by investigators

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Response rate, Toxicity
Secondary Outcome Measures
NameTimeMethod
Progression free survival, Quality of life
© Copyright 2025. All Rights Reserved by MedPath